Hyderabad / New Delhi — March 22, 2026
Dr Reddy’s Launches Affordable Semaglutide in India
Dr Reddy’s Laboratories has launched India’s first affordable generic version of semaglutide, a widely used drug for Type 2 diabetes and weight management, following the expiry of key patents on branded versions.
The weekly injection is priced at approximately ₹4,200 per month, making it significantly more accessible compared to imported alternatives.
What Is Semaglutide and How It Works
Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists. It works by mimicking a natural hormone that regulates blood sugar levels and appetite.
- Helps control blood glucose in Type 2 diabetes
- Reduces appetite, supporting weight loss
- Administered via a weekly subcutaneous injection
The launch includes user-friendly injection pens designed for easy self-administration.
Major Boost for Accessibility in India
India has one of the largest populations affected by diabetes, with an estimated 77 million cases, according to international health data.
The introduction of a lower-cost generic version is expected to expand access to advanced treatment options that were previously limited due to high costs.
Company officials emphasized that affordability is key to reaching a broader patient base, especially in a market where imported drugs like Ozempic and Wegovy have remained expensive.
Market Impact and Industry Response
The launch is likely to intensify competition in India’s pharmaceutical sector. Other major companies such as Sun Pharma and Cipla are expected to enter the market with similar generic versions.
The move aligns with India’s broader strategy to promote domestic drug manufacturing and reduce dependence on imports.
Industry experts believe this could:
- Lower treatment costs for patients
- Increase adoption of advanced therapies
- Strengthen India’s position in global generics
Safety, Monitoring, and Regulatory Considerations
While the drug improves accessibility, experts highlight the need for careful monitoring of side effects and proper medical supervision.
There are also concerns about the potential rise of counterfeit products as demand increases, making regulatory vigilance essential.
Healthcare professionals advise patients to use semaglutide only under prescription and follow medical guidance closely.
A Step Toward Affordable Advanced Healthcare
The launch of generic semaglutide marks a significant development in India’s healthcare landscape, offering a more affordable solution for managing diabetes and obesity.
It reflects a broader shift toward accessible, cost-effective treatments while supporting innovation and growth in the pharmaceutical sector.
